Signs collaboration agreement with AstraZeneca to offer
state-of-the-art technology to clients
WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 1, 2018--
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced a new agreement which grants Charles River commercial access
to AstraZeneca’s (NYSE: AZN) high-throughput screening (HTS) and
compound management infrastructure. Through the agreement, Charles River
will perform HTS programs for its clients utilizing AstraZeneca’s
state-of-the-art HTS facility.
Charles River will place scientists-in-residence at AstraZeneca’s Centre
for Lead Discovery in Cambridge, United Kingdom, to manage its compound
collection and run HTS for clients with a comprehensive range of assay
technologies, liquid handling platforms, and automated storage systems.
The highly dynamic and brand-new compound management and HTS facility is
equipped to provide efficient drug discovery screening services from
assay conception to hit identification.
SLAS2018 International Conference and Exhibition
River will debut its enhanced HTS offering, which includes a recent
expansion of its in-house compound library, during SLAS2018, the annual
flagship conference for the Society for Laboratory Automation and
Screening being held February 3-7, 2018, in San Diego, CA. Conference
attendees can meet with Charles River experts at Booth #1746 to discuss
HTS, along with the Company’s comprehensive portfolio of drug discovery
and development services.
Additionally, David Cronk, Director of Hit Discovery at Charles River,
will present a tutorial, A Perspective on the Use of Stem Cells in
High-Throughput Screening, on Tuesday, February 6, 2018, from
12:30-1:15 p.m. To learn more about Charles River’s presence at
SLAS2018, click here.
“Providing our clients access to AstraZeneca’s HTS technology enhances
our existing capabilities by broadening our assay platforms and
increasing our ability to automate, ultimately allowing us to execute
HTS projects with greater speed and accuracy.” –Ian Waddell, Ph.D.,
Executive Director, Biology at Charles River
“Through our longstanding relationship with AstraZeneca, we have
developed and implemented best practices that allow us to complete
studies more efficiently and effectively. Access to AstraZeneca’s HTS
technology is another collaboration that will enable us to continue to
deliver groundbreaking science.” –Brian Bathgate, Ph.D., Corporate
Senior Vice President, European Safety Assessment at Charles River
“We look forward to welcoming Charles River’s scientists to our
state-of-the-art facilities in the UK Centre for Lead Discovery. This
demonstrates AstraZeneca’s open and collaborative approach to drug
discovery and further establishes the UK Centre for Lead Discovery as
a leading global centre for Hit Discovery.” –Mark Wigglesworth,
Director High Throughput Screening at AstraZeneca’s IMED Biotech Unit
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their research
and drug development efforts. Our dedicated employees are focused on
providing clients with exactly what they need to improve and expedite
the discovery, early-stage development and safe manufacture of new
therapies for the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180201005110/en/
Source: Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc.
E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
Amy Cianciaruso, 781-222-6168
President, Public Relations